- Ventrus Biosciences' (VTUS) Diltiazem Cream to treat patients with anal fissures improved their symptoms in a second Phase III trial, as expected.
- However, the placebo effect in the control group was greater than anticipated, resulting in no significant difference between the treatments.
- In the first pivotal Phase 3 trial, Diltiazem did perform better than the placebo.
- Ventrus plans to request a pre-NDA meeting with the FDA to determine its next steps. (PR)
at CNBC.com (Feb 12, 2014)